9h
Zacks.com on MSNVertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowVertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...
In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...
Looking for a good area in which to invest? Consider the healthcare sector. People must have healthcare. And with aging ...
Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to ...
Learn more about whether Alnylam Pharmaceuticals, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on ...
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...
Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results